Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine

Details

• Alternative Title:
  Pediatrics
• Personal Author:
  Cohn, Amanda C. ; MacNeil, Jessica R. ; Harrison, Lee H. ; Lynfield, Ruth ; Reingold, Arthur ; Schaffner, William ; Zell, Elizabeth R. ; Plikaytis, Brian ; Wang, Xin ; Messonnier, Nancy E.
• Description:
  BACKGROUND:
  
  Meningococcal conjugate vaccines were licensed beginning in 2005 on the basis of serologic end points and recommended for use in adolescents. A single dose at age 11 to 12 years was expected to provide protection through late adolescence. We conducted a case-control evaluation of vaccine effectiveness (VE) and duration of protection of a meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D).
  
  METHODS:
  
  Cases of culture- or polymerase chain reaction-confirmed serogroup A, C, W, and Y meningococcal disease among adolescents were identified through meningococcal disease surveillance sites in the United States from January 1, 2006, through August 31, 2013. Attempts were made to enroll 4 friend and school controls per case. VE was calculated using the generalized estimating equation, controlling for underlying medical conditions and smoking.
  
  RESULTS:
  
  Serogroup C accounted for 88 (49%), serogroup Y 80 (44%), and serogroup W 13 (7%) of enrolled cases. Thirty-six (20%) cases and 87 (44%) controls received MenACWY-D. The overall VE estimate 0 to 8 years postvaccination was 69% (51% to 80%); VE was 79% (49% to 91%) at <1 year, 69% (44% to 83%) at 1 to <3 years, and 61% (25% to 79%) at 3 to <8 years. VE was 77% (57% to 88%) against serogroup C and 51% (1% to 76%) against serogroup Y.
  
  CONCLUSIONS:
  
  MenACWY-D was effective in the first year after vaccination but effectiveness waned 3 to <8 years postvaccination. The estimates of VE from this evaluation informed the Advisory Committee on Immunization Practices in its decision to add a booster dose of MenACWY.
  
  
• Subjects:
  Adolescent Antibodies, Bacterial Carrier State Case-Control Studies Child Female Follow-Up Studies Humans Immunization, Secondary Male Meningococcal Infections Meningococcal Vaccines Population Surveillance Treatment Outcome Young Adult

  More +
• Source:
  Pediatrics. 139(2)
• Pubmed ID:
  28100689
• Pubmed Central ID:
  PMC8353579
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Place as Subject:
  United States
• Volume:
  139
• Issue:
  2
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:4f0ec20e14ffe6a29fec1a1cdc111eb8ab46662990667559fa9446dd4cf77c13
• Download URL:
  https://stacks.cdc.gov/view/cdc/108755/cdc_108755_DS1.pdf
• File Type:
  [PDF - 357.01 KB ]